The DXL Calscan™ Bone Densitometer estimated bone mineral density (BMD) (g/cm²) for the region of the heel (os calcis). By comparing estimated BMD to a (grim ) for the region of the Rose (a T-score is calculated so that the physician, at his or her discretion, may assess fracture risk.

Device Description

The DXL Calscan™ Bone Densitometer estimates Bone Mineral Density (BMD) of the Os Calcis. THE DAL Calstan - Bone Densitometor Societator Sectionetry (DEXA). Heel width, measured by a The lectificiously is based on Dual Enorgy Artay Arage in the effects from soft and adipose tissues.

AI/ML Overview

Here's an analysis of the provided text regarding the DXL Calscan Bone Densitometer's acceptance criteria and study information:

Summary of Device Acceptance Criteria and Performance

Acceptance Criteria Category	Acceptance Criteria (from text)	Reported Device Performance (from text)
In vitro Accuracy	(Implied to be high correlation with actual content)	Correlation (r) = 0.99 between estimated BMD and actual hydroxyapatite content.
In vitro Short-Term Precision (BMD)	(Implied to be low variability)	BMD precision error (CV%) = 0.77%
In vitro Laser Ruler Short-Term Precision	(Implied to be low variability)	CV% = 0.01%
In vitro Laser Ruler Accuracy	(Implied to be low error)	Accuracy error = 1.5%
In vivo Short-Term Precision (BMD)	(Implied to be low variability)	BMD precision error (CV%) = 1.2%
Scan Time	(Not explicitly stated as an acceptance criterion, but a characteristic)	55 seconds
Effective Patient Dose	(Not explicitly stated as an acceptance criterion, but a characteristic)	0.02 mrem
Substantial Equivalence	To predicate devices (PIXI Bone Densitometer, DTX-200 Bone Densitometer)	Concluded to be substantially equivalent with no new safety or effectiveness questions.

Study Information

Sample sizes used for the test set and the data provenance:
- The provided text does not specify the sample sizes used for the in vitro or in vivo precision and accuracy studies.
- Data provenance: Not explicitly stated (e.g., country of origin, retrospective or prospective). The company is Swedish (Demetech AB, Solna, Sweden), so it's possible studies were conducted in Sweden, but this is not confirmed.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- The document does not provide information on the number or qualifications of experts used to establish ground truth for the in vivo studies.
- For in vitro studies, the "actual hydroxyapatite content" likely serves as a direct reference, not requiring expert consensus in the same way.
Adjudication method (e.g., 2+1, 3+1, none) for the test set:
- The document does not describe an adjudication method.
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No MRMC comparative effectiveness study is mentioned. This device is a bone densitometer, which directly measures BMD and does not involve human interpretation of images per se that would typically require an MRMC study or AI assistance for human readers.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Yes, the performance metrics (accuracy, precision, CV%) are for the DXL Calscan™ Bone Densitometer itself, which is an automated device for measuring BMD. These are standalone performance metrics.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- For the in vitro accuracy study, the ground truth was "actual hydroxyapatite content."
- For the in vivo precision study, the ground truth for precision is typically the repeated measurement itself, a comparator for accuracy is not explicitly stated but would ideally be a gold standard BMD measurement technique.
The sample size for the training set:
- The document does not specify a training set sample size. This is common for predicate-based 510(k) submissions, especially for a device performing direct physical measurements rather than learning complex patterns from a large dataset like an AI algorithm.
How the ground truth for the training set was established:
- The document does not specify how a ground truth for a training set was established, nor does it indicate the use of a distinct "training set" in the context of machine learning. The studies described are performance validation studies.

Summary

{0}------------------------------------------------

KO33550

Image /page/0/Picture/2 description: The image shows the word "demetech" in bold, black letters. Above the word are three small, faint circles arranged horizontally. To the left of the word is a partial circular design, also faint, that appears to be made up of small lines or strokes.

5.0 510 (k) SUMMARY

Information shown in this section is furnished in accordance with 21CFR807.92. The paragraph headings correspond directly with those in 21CFR807.92

807.92(a)(1) Name, address, telephone number, contact person and preparation date

Submitters name and address: .
Demetech AB Dalvägen 24 169 56 Solna Sweden

Submitters telephone number .

Phone:	+46 8 555 79 204
Cell:	+46 733 10 50 91
Fax:	+46 8 555 79 249
E-mail:	joakim.arwidson@demetech.se

Contact person . Joakim Arwidson International Product Manager Demetech AB Dalvägen 24 169 56 Solna Sweden

Preparation date . November 7, 2003

807.92(a)(2) Proprietary/Trade name, Common name, Classification name

Proprietary/Trade name . DXL Calscan™
Common name . Bone Densitometer
Classification name . Bone Densitometer, 21CFR892.1170

DEME 11-CH AR PostStaddress 140% 3890. M 1996 BONDANIA DAST OF N.

Chemics addrenss 1997 1981 11:34 11 11 11 11 11 11 11 100 0000

6 # # 8 # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # # and source and a so 17. x = =

NE O@DEMI-TECB COM WAAR DEBRE TT CH COM

{1}------------------------------------------------

Image /page/1/Picture/0 description: The image shows the word "demetech" in a bold, sans-serif font. There is a partial parenthesis to the left of the word and three circles above the "tech" portion of the word. The text and symbols are all in black and white. The image appears to be a logo or brand name.

807.92(a)(3) Legally marketed device (predicate device)

PIXI Bone Densitometer, GE Lunar, 510(k) K970224 & K983262 .
DTX-200 Bone Densitometer, Osteometer Meditech, 510(k) K964562 .

807.92(a)(4) Description of the device that is subject of this premarket notification

807.92(a)(5) Intended use

The DXL Calscan™ Bone Densitometer estimates bone mineral density (BMD) (g/cm3) for the The DXL Galscan - Bone Donomotor other the BMD to a physician-selected reference region of the nece (os oalor). By ochipatible of his or her discretion, may assess fracture risk.

807.92(a)(6) Technological characteristics

One patient scan with DXL Calscan takes 55 seconds to perform. The effective patient dose is 0.02 One patient scan with DXL Oalooan takes by loser ruler with a maximum power of 5 mW and wavelength 635 nm.

807.92(b)(1) Brief discussion of the nonclinical tests submitted, referenced or relied on in this premarket notification submission.

DXL Calscan in vitro Accuracy Study shows correlation (r=0.99) between estimated BMD and actual hydroxyapatite content.

DXL Calscan in vitro Short-Term Precision Study shows BMD precision error (CV%) of 0.77%.

DXL Calscan in vitro Laser Ruler Study shows short-term precision error (CV%) of 0.01% and an accuracy error of 1.5%.

807.92(b)(2) Brief discussion of the clinical tests submitted, referenced or relied on in this premarket notification submission.

DXL Calscan in vivo Short-Term Precision Study shows BMD precision error (CV%) of 1.2%.

{2}------------------------------------------------

Image /page/2/Picture/0 description: The image shows the word "demetech" in a bold, sans-serif font. There are three small circles above the "tech" portion of the word. A curved line is present on the left side of the word, resembling a parenthesis. The text is black and the background is white.

807.92(b){3} Conclusions drawn from the nonclinical and clinical tests that demonstrate that 807.92(0)(3) Conclusions drawn from the nonomical and should or better than the predicate device.

Based on the results from the tests, the DXL Calscan™ Bone Definetive se sustantially Based on the results from the tests, the DAL Ouround - Bone Bellenshill.
equivalent to previously registered devices. No new safety and effectiveness questions are raised with the DXL Calscan Bone Densitometer.

DEMETECH AB Postal address ROK 30345 SE 1300 C North NG ないのではな

Misiline addiness DAL PAGE N. A. 照 - bed56 beg36 2007年度上。

1990 PM = 044-05 300 2001 144 8 555 79 249 !バメ

NFO@DFDF.0F.TCCH COM www.Delar. TECH Com

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized depiction of an eagle or bird-like figure with three curved lines representing its body and wings. The logo is encircled by the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" in a circular arrangement.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Mr. Joakim Arwidson International Product Manager DEMETECH AB Box 3095 SE-16903 Solna SWEDEN

Rc: K033550

Trade/Device Name: DXL Calscan Bone Densitometer Regulation Number: 21 CFR 892.1170 Regulation Name: Bone densitometer Regulatory Class: II Product Code: 90 KGI Dated: March 14, 2004 Received: March 16, 2004

Dear Mr. Arwidson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

MAY - 5 2004

{4}------------------------------------------------

This letter will allow you to begin marketing your device as described in your Section 510(k) I this lotter will and TOA finding of substantial equivalence of your device to a legally premantee nodicated. " Tresults in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of the letter:

8xx.1xxx	(301) 594-4591
876.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4616
884.2xxx, 3xxx, 4xxx, 5xxx, 6xxx	(301) 594-4616
892.2xxx, 3xxx, 4xxx, 5xxx	(301) 594-4654
Other	(301) 594-4692

Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Nancy C. Broughton

Nancy C. Brogdon Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

INDICATION FOR USE FORM 8.0

510(k) Number (if known) _033550 .
Device Name: DXL Calscan .
. Indications for use:

One patient scan with DXL Calscan takes 55 seconds to perform. The effective One patient dose is 0.02 mrem. This performance is substantially equivalent to PIXI performance and poses no new safety or efficacy concerns.

Use of the DXL Calscan is restricted to prescription use only. The Operator's Manual for the DXL Calscan contains the following statement:

"United States Federal Law restricts this device to the sale, distribution and use by or on the order of a physician."

PLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED.

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) OR

Over-the-Counter Use

(Optional Format 1-2-96)

David Ro. Ingram

(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices

510(k) Number

Regulation Number and Section

§ 892.1170 Bone densitometer.

(a)
Identification. A bone densitometer is a device intended for medical purposes to measure bone density and mineral content by x-ray or gamma ray transmission measurements through the bone and adjacent tissues. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II.